BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib

Irreversible inhibitors of Bruton tyrosine kinase (BTK), pioneered by ibrutinib, have become breakthrough drugs in the treatment of leukemias and lymphomas. Resistance variants (mutations) occur, but in contrast to those identified for many other tyrosine kinase inhibitors, they affect less frequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Estupiñán, H. Yesid, Wang, Qing, Berglöf, Anna, Schaafsma, Gerard C. P., Shi, Yuye, Zhou, Litao, Mohammad, Dara K., Yu, Liang, Vihinen, Mauno, Zain, Rula, Smith, C. I. Edvard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102192/
https://www.ncbi.nlm.nih.gov/pubmed/33526860
http://dx.doi.org/10.1038/s41375-021-01123-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102192/
https://www.ncbi.nlm.nih.gov/pubmed/33526860
http://dx.doi.org/10.1038/s41375-021-01123-6

Ejemplares similares